| scholarly article | Q13442814 |
| P50 | author | Paul Dent | Q73523499 |
| P2093 | author name string | Shuang Chen | |
| Steven Grant | |||
| Yun Dai | |||
| Payal Khanna | |||
| Xin-Yan Pei | |||
| P2860 | cites work | The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01 | Q28145108 |
| Targeting RAS signalling pathways in cancer therapy | Q28201363 | ||
| Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models | Q28212532 | ||
| Phospholipase C(epsilon): a novel Ras effector | Q28348875 | ||
| Activation of Ras up-regulates pro-apoptotic BNIP3 in nitric oxide-induced cell death | Q28505436 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis | Q29547567 | ||
| Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway | Q29616436 | ||
| Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane | Q29618478 | ||
| Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. | Q45242264 | ||
| A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors | Q45258277 | ||
| Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain | Q46272398 | ||
| Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor | Q46402596 | ||
| Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies | Q46679447 | ||
| Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. | Q53403767 | ||
| A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. | Q54278046 | ||
| Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach | Q58327250 | ||
| Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets | Q71946178 | ||
| Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? | Q33915429 | ||
| BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. | Q33960826 | ||
| Anti-cancer therapy: targeting the mevalonate pathway | Q33993535 | ||
| Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors | Q34207135 | ||
| Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy | Q34412215 | ||
| Therapy insight: Potential of statins for cancer chemoprevention and therapy | Q34464661 | ||
| HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis | Q34605246 | ||
| Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation | Q35542787 | ||
| Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents | Q35642631 | ||
| Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer | Q35942311 | ||
| Review of UCN-01 development: a lesson in the importance of clinical pharmacology | Q36075195 | ||
| The role of statins in cancer prevention and treatment. | Q36170997 | ||
| Development of farnesyl transferase inhibitors: a review | Q36263983 | ||
| HMG-CoA reductase inhibitors (statins) as anticancer drugs (review). | Q36279865 | ||
| Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors | Q36288714 | ||
| Cell cycle regulatory kinase modulators: interim progress and issues | Q36296629 | ||
| Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma | Q36445971 | ||
| Statin use and cancer risk: an epidemiologic review | Q36508082 | ||
| IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. | Q38343244 | ||
| Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells | Q40238359 | ||
| Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth | Q40345613 | ||
| The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells | Q40408755 | ||
| c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. | Q40502581 | ||
| In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines | Q40527964 | ||
| Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. | Q40541674 | ||
| The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase | Q40552228 | ||
| Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells | Q40612929 | ||
| Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response | Q40683311 | ||
| Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoB. | Q40757461 | ||
| Interaction of cytosine arabinoside and lovastatin in human leukemia cells | Q40800348 | ||
| Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis | Q42467738 | ||
| Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling | Q42484129 | ||
| Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival | Q42807667 | ||
| Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells | Q43657350 | ||
| Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells | Q43714923 | ||
| Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). | Q43919081 | ||
| Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism | Q44182944 | ||
| Isoprenoids influence expression of Ras and Ras-related proteins | Q44212892 | ||
| Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. | Q44215095 | ||
| Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses | Q44265497 | ||
| Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression | Q44277460 | ||
| Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways | Q44435112 | ||
| Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels | Q44509632 | ||
| Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). | Q44876787 | ||
| Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. | Q44905929 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 4415-4423 | |
| P577 | publication date | 2007-01-30 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation | |
| P478 | volume | 109 |
| Q35553393 | 12/15-Lipoxygenase gene knockout severely impairs ischemia-induced angiogenesis due to lack of Rac1 farnesylation. |
| Q36750940 | A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer |
| Q47622968 | ATR/CHK1 inhibitors and cancer therapy |
| Q41959819 | Apoptosis, autophagy and ER stress in mevalonate cascade inhibition-induced cell death of human atrial fibroblasts |
| Q24622357 | CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle |
| Q89620715 | Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy |
| Q39647685 | Combined Inhibitory Effects of Celecoxib and Fluvastatin on the Growth of Human Hepatocellular Carcinoma Xenografts in Nude Mice |
| Q48690287 | Differential roles of the mevalonate pathway in the development and survival of mouse Purkinje cells in culture |
| Q34667764 | Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo |
| Q58763293 | ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells |
| Q53573242 | Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats. |
| Q38112176 | Emerging pathways as individualized therapeutic target of multiple myeloma. |
| Q54558882 | Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation. |
| Q36868759 | Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells |
| Q35861885 | JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth |
| Q35990714 | MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism |
| Q41162635 | Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation |
| Q34129155 | New insights into checkpoint kinase 1 in the DNA damage response signaling network |
| Q38180769 | New strategies for the treatment of ovarian cancer |
| Q37016007 | PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma |
| Q39195848 | Preclinical evaluation of statins as a treatment for ovarian cancer. |
| Q35750491 | Rational Combinations of Targeted Agents in AML |
| Q34022639 | Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras |
| Q54976846 | STK3 is a therapeutic target for a subset of acute myeloid leukemias. |
| Q38770832 | Simvastatin inhibits protein isoprenylation in the brain. |
| Q39392253 | Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation. |
| Q33816591 | Statins Are Associated With Reduced Mortality in Multiple Myeloma |
| Q91594463 | Statins Perturb Gβγ Signaling and Cell Behavior in a Gγ Subtype Dependent Manner |
| Q39967982 | Statins activate a mitochondria-operated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the prenylation of proteins |
| Q47679039 | Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells |
| Q38976416 | Suppressive effects of simvastatin on the human acute promyelocytic leukemia NB4 cell line through the regulation of the nuclear factor-κB signaling pathway |
Search more.